Loading stock data…
HSIC
$73.93-0.66 (-0.88%)
Market ClosedLast close May 1
Henry Schein, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Henry Schein, Inc. in the Healthcare sector is trading at $73.93. The stock is currently 17% below its 52-week high of $89.29, remaining 1.8% above its 200-day moving average. Technical signals show neutral RSI of 40 and bearish MACD signal, explaining why HSIC maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 40) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$73.93
Potential Downside
14.6%
Whystock Fair Value$63.13
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Buy
Mean target$90.21+22.0%
Range$64.00 – $104.00
Fundamentals
Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.96B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
23.89
Beta
Defensive asset. Lower volatility than the S&P 500.
0.88
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
11.99%
Volume
Today's trading volume
1.78M
Recent News
Henry Schein Inc. (HSIC): David Einhorn Is Buying This Health Stock
We just covered 15 Under-the-Radar Picks from David Einhorn That Are Quietly Dominating 2026 and Henry Schein, Inc. (NASDAQ:HSIC) ranks 10th on this list. Henry Schein, Inc. (NASDAQ:HSIC) is a new addition to the 13F portfolio of Greenlight Capital. Filings for the fourth quarter of 2025 show that the fund owned 460,000 shares in the firm. […]
Staar Surgical (STAA) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Henry Schein (HSIC) Reports Next Week: Wall Street Expects Earnings Growth
Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Henry Schein Is Placed Ahead of Q1 Earnings
HSIC heads into Q1 earnings results with steady estimates, a 5.1% revenue growth outlook and strength across distribution, specialty products and tech.
Will DXCM's G7 Uptake Continue to Drive Top-line Growth in Q1?
DexCom's Q1 results may see strong growth from G7 uptake and CGM demand, but pricing mix and rising investments could weigh on margins.